192 related articles for article (PubMed ID: 19647224)
1. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.
Oravecz-Wilson KI; Philips ST; Yilmaz OH; Ames HM; Li L; Crawford BD; Gauvin AM; Lucas PC; Sitwala K; Downing JR; Morrison SJ; Ross TS
Cancer Cell; 2009 Aug; 16(2):137-48. PubMed ID: 19647224
[TBL] [Abstract][Full Text] [Related]
2. Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
Philips ST; Hildenbrand ZL; Oravecz-Wilson KI; Foley SB; Mgbemena VE; Ross TS
Oncogene; 2014 Nov; 33(46):5379-90. PubMed ID: 24240679
[TBL] [Abstract][Full Text] [Related]
3. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
4. A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment.
Buijs A; van Wijnen M; van den Blink D; van Gijn M; Klein SK
Cancer Genet; 2013 Apr; 206(4):140-4. PubMed ID: 23751892
[TBL] [Abstract][Full Text] [Related]
5. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.
Naka K; Hoshii T; Muraguchi T; Tadokoro Y; Ooshio T; Kondo Y; Nakao S; Motoyama N; Hirao A
Nature; 2010 Feb; 463(7281):676-80. PubMed ID: 20130650
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
8. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
9. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
[TBL] [Abstract][Full Text] [Related]
10. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
Ritchie KA; Aprikyan AA; Bowen-Pope DF; Norby-Slycord CJ; Conyers S; Bartelmez S; Sitnicka EH; Hickstein DD
Leukemia; 1999 Nov; 13(11):1790-803. PubMed ID: 10557054
[TBL] [Abstract][Full Text] [Related]
11. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.
Magnusson MK; Meade KE; Nakamura R; Barrett J; Dunbar CE
Blood; 2002 Aug; 100(3):1088-91. PubMed ID: 12130532
[TBL] [Abstract][Full Text] [Related]
12. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC
Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes.
Mitkevich VA; Petrushanko IY; Spirin PV; Fedorova TV; Kretova OV; Tchurikov NA; Prassolov VS; Ilinskaya ON; Makarov AA
Cell Cycle; 2011 Dec; 10(23):4090-7. PubMed ID: 22101339
[TBL] [Abstract][Full Text] [Related]
14. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
Holtz MS; Bhatia R
Leuk Lymphoma; 2004 Feb; 45(2):237-45. PubMed ID: 15101707
[TBL] [Abstract][Full Text] [Related]
15. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.
Grisolano JL; O'Neal J; Cain J; Tomasson MH
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9506-11. PubMed ID: 12881486
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate in the treatment of hematologic malignancies.
Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
[TBL] [Abstract][Full Text] [Related]
17. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
18. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
[No Abstract] [Full Text] [Related]
19. TV6 and PDGFRB: a license to fuse.
Lierman E; Cools J
Haematologica; 2007 Feb; 92(2):145-7. PubMed ID: 17296561
[No Abstract] [Full Text] [Related]
20. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
[No Abstract] [Full Text] [Related]
[Next] [New Search]